AllQuantitative Report
Argus•October 15, 2020
Argus•October 15, 2020XNCR: Lowering target price to $43.00
Summary
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to tre
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Technical Assessment: Neutral in the Intermediate-TermApr 22, 2024 •
CVX, PFE
- Daily Spotlight: Demand Shifts for U.S. DebtApr 19, 2024 •
BIIB
- Analyst Report: AbbVie IncApr 18, 2024 •
ABBV
- Market Digest: BK, ABBVApr 18, 2024 •
BK, ABBV
- RGNX: Lowering target price to $18.00Apr 17, 2024 •
RGNX